eif3ea Antibody

What is EIF3E and what is its primary function in cellular processes?

EIF3E (Eukaryotic Translation Initiation Factor 3 Subunit E) is a critical component of the EIF3 complex, which plays an essential role in protein synthesis initiation. The EIF3 complex is involved in the recruitment of ribosomes to mRNA and the assembly of the translation initiation complex. EIF3E specifically contains RNA-binding motifs necessary for the protein synthesis initiation process . While EIF3E is ubiquitously expressed at low levels in normal adult tissues, its expression is elevated in proliferating tissues such as bone marrow and fetal tissues, suggesting important roles in biological processes related to cell growth and development .

What types of EIF3E antibodies are available for research applications?

Several types of EIF3E antibodies are available for research purposes, varying in host, reactivity, and applications. The most common types include rabbit polyclonal antibodies, though mouse polyclonal and goat polyclonal antibodies are also available . These antibodies can target different regions of the EIF3E protein, including N-terminal regions, C-terminal regions, middle regions, and full-length proteins . Some antibodies recognize specific amino acid sequences, such as those targeting AA 248-276, AA 346-445, or AA 36-85 . The selection of the appropriate antibody depends on the experimental design and target species.

How should researchers determine which EIF3E antibody is appropriate for their specific experimental design?

Researchers should consider several factors when selecting an EIF3E antibody:

• Target species reactivity: Verify the antibody recognizes your species of interest (human, mouse, rat, etc.)

• Application compatibility: Ensure the antibody is validated for your intended application (WB, IF, IHC, ELISA)

• Epitope location: Select antibodies targeting relevant regions of the protein based on research question

• Clonality: Polyclonal antibodies offer broader epitope recognition, while monoclonal antibodies provide higher specificity

• Host species: Choose a host that avoids cross-reactivity with other antibodies in multi-labeling experiments

For instance, if studying EIF3E in human and mouse samples using Western blotting and immunofluorescence, researchers should select an antibody like the rabbit polyclonal antibody that demonstrates reactivity with both species and is validated for both applications .

What is the relationship between EIF3E, EIF3A, and cancer progression?

Recent research has established important connections between eukaryotic translation initiation factors and cancer. While EIF3E is a component of the EIF3 complex, EIF3A (the largest subunit of the complex) has been increasingly linked to cancer progression . Studies have shown that EIF3A expression is significantly elevated in hepatocellular carcinoma (HCC) tissues compared to normal tissues, both in mouse models and human patients . Analysis using Gene Expression across Normal and Tumor tissue (GENT) confirmed that EIF3A is significantly increased in human liver cancer compared to normal tissue (p < 0.0001) . This elevation in expression suggests that these translation initiation factors may play critical roles in cancer development, making them potential targets for both diagnostic and therapeutic approaches.

What are the validated research applications for EIF3E antibodies?

Based on the available data, EIF3E antibodies have been validated for several research applications:

• Western Blotting (WB): For detecting and quantifying EIF3E protein expression in cell or tissue lysates

• Immunofluorescence (IF): For visualizing the cellular localization of EIF3E protein

• Immunohistochemistry (IHC): For examining EIF3E expression in tissue sections

• ELISA: For quantitative detection of EIF3E in various samples

• Immunochromatography (IC): For rapid detection applications

The specific antibody ABIN7306290, for example, has been validated for Western Blotting, Immunofluorescence, and Immunochromatography, with confirmed specificity for endogenous levels of eIF3E protein . Researchers should verify the validation status for their particular application before proceeding with experiments.

How should researchers optimize immunofluorescence protocols when using EIF3E antibodies?

For optimal immunofluorescence results with EIF3E antibodies, researchers should follow these methodological guidelines:

• Fixation: Use 4% paraformaldehyde for 15-20 minutes at room temperature to preserve cellular structures while maintaining epitope accessibility

• Permeabilization: Apply 0.1-0.5% Triton X-100 for 5-10 minutes to allow antibody access to intracellular targets

• Blocking: Block with 5% normal serum from the same species as the secondary antibody for 1 hour to reduce non-specific binding

• Primary antibody dilution: Optimize dilutions through titration experiments (typically 1:100 to 1:500 range)

• Incubation conditions: Incubate with primary antibody overnight at 4°C to increase specific binding

• Controls: Always include no-primary antibody controls and, if possible, knockdown/knockout samples as negative controls

• Signal amplification: Consider using signal amplification systems for detecting low-abundance targets

Based on successful applications, researchers have detected EIF3E in human HCC HepG2 cells as well as mouse hepatoma Hepa-1c1c7 cells using immunofluorescence analysis with appropriate antibodies .

What experimental validation methods should be used to confirm EIF3E antibody specificity?

To ensure experimental rigor, researchers should validate EIF3E antibody specificity using multiple complementary approaches:

• Knockdown/knockout validation: Perform siRNA knockdown or CRISPR-mediated knockout of EIF3E and confirm reduced or absent signal in Western blot or immunostaining assays

• Immunoprecipitation verification: Immunoprecipitate EIF3E with the antibody and confirm identity by mass spectrometry

• Competing peptide assays: Pre-incubate the antibody with the immunizing peptide and demonstrate signal reduction

• Multiple antibody comparison: Use antibodies targeting different epitopes of EIF3E and confirm similar patterns

• Recombinant protein controls: Use purified recombinant EIF3E protein as a positive control

The search results demonstrate the effective use of such validation methods, as researchers verified EIF3A as the target antigen for the XC90 antibody through knockdown experiments, overexpression studies, and immunoprecipitation followed by Western blot analysis .

How can EIF3E/EIF3A antibodies be utilized for cancer biomarker development?

Research demonstrates that EIF3A autoantibodies can serve as potential diagnostic biomarkers for hepatocellular carcinoma. The methodological approach involves:

• Epitope identification: Screen for specific conformational epitopes from random cyclic peptide libraries that selectively bind to the autoantibodies

• Epitope-display system development: Express the identified epitopes as fusion proteins with carrier molecules like streptavidin

• Assay optimization: Develop ELISA protocols using the epitope-display system as capture antigens

• Clinical validation: Test the assay on patient and control samples to establish sensitivity and specificity

Using this approach, researchers developed an ELISA for anti-EIF3A autoantibody detection that distinguished HCC patients from healthy controls with a sensitivity of 79.4% and specificity of 83.5% (AUC = 0.87) . Notably, when combined with other HCC biomarkers like alpha-fetoprotein, the diagnostic sensitivity improved further from 79.4% to 85% .

What are the methodological considerations for detecting EIF3E/EIF3A in exosomes and their potential role in cancer diagnostics?

The detection of EIF3E/EIF3A in exosomes presents unique methodological challenges and opportunities:

• Exosome isolation: Optimize ultracentrifugation, size exclusion chromatography, or commercial kits for consistent exosome recovery

• Sample preparation: Carefully lyse exosomes using appropriate buffers while preserving protein integrity

• Antibody selection: Choose antibodies validated for exosome-derived proteins, which may have different post-translational modifications

• Quantification methods: Develop standardized Western blot, ELISA, or mass spectrometry protocols for exosomal EIF3E/EIF3A

• Normalization strategies: Normalize to exosomal markers (CD63, CD81) to account for variations in exosome recovery

Research has identified EIF3A in tumor-derived exosomes, which appears to be a potential cause of tumor-associated autoantibody production . This finding suggests that exosomal EIF3A may serve as a cancer biomarker and offers insights into the mechanisms underlying autoantibody generation in cancer patients.

What approaches should be used to analyze EIF3E expression across different cancer stages and types?

For comprehensive analysis of EIF3E expression across cancer stages and types, researchers should employ a multi-modal approach:

• Transcriptomic analysis: Utilize RNA-seq or microarray data to examine EIF3E mRNA expression

• Protein quantification: Perform Western blotting or mass spectrometry for protein-level analysis

• Tissue examination: Conduct immunohistochemistry on tissue microarrays covering different cancer stages

• Single-cell analysis: Apply single-cell RNA-seq or mass cytometry to assess cellular heterogeneity

• Correlation studies: Analyze relationships between EIF3E expression and clinical parameters

Research on EIF3A expression in HCC demonstrated significantly increased levels in tumor tissues compared to normal tissues across different tumor stages . The table below summarizes findings on anti-EIF3A autoantibody detection across HCC patients:

Notably, anti-EIF3A autoantibodies were detected across all tumor stages and sizes, including early-stage tumors and small tumor burden (<2 cm), suggesting potential utility for early cancer detection .

How should researchers address non-specific binding issues when using EIF3E antibodies in Western blotting?

Non-specific binding in Western blotting with EIF3E antibodies can be addressed through systematic optimization:

• Blocking optimization: Test different blocking agents (5% non-fat milk, 5% BSA, commercial blocking buffers) to identify the most effective option

• Antibody dilution: Perform titration experiments to determine optimal primary antibody concentration

• Washing stringency: Increase washing duration or detergent concentration (0.1-0.5% Tween-20) in wash buffers

• Buffer composition: Adjust salt concentration in antibody diluent (150-500 mM NaCl) to reduce non-specific ionic interactions

• Membrane selection: Compare PVDF and nitrocellulose membranes for optimal signal-to-noise ratio

• Pre-adsorption: Pre-incubate antibody with unrelated proteins to reduce cross-reactivity

• Alternative antibody: Test antibodies targeting different epitopes of EIF3E

Research validating XC90 antibody reactivity to cancer cell lysates by Western blotting confirmed specific detection of an antigen approximately 150 kDa in molecular weight, demonstrating successful optimization of Western blotting conditions .

What strategies can resolve contradictory results when comparing different detection methods for EIF3E/EIF3A?

When faced with contradictory results from different detection methods, researchers should implement the following analytical and troubleshooting strategies:

• Method-specific controls: Include appropriate positive and negative controls for each detection method

• Epitope accessibility assessment: Consider whether sample preparation differentially affects epitope exposure across methods

• Antibody validation: Verify antibody specificity using multiple approaches for each detection method

• Cross-platform standardization: Develop standardized protocols and reference materials for cross-method comparison

• Quantitative analysis: Apply statistical approaches to determine significant differences and variation sources

• Biological context integration: Interpret results within the biological context of the system being studied

• Multi-antibody approach: Use multiple antibodies targeting different epitopes to confirm results

How can researchers optimize ELISA protocols for detecting anti-EIF3A autoantibodies in clinical samples?

The optimization of ELISA protocols for anti-EIF3A autoantibody detection requires careful consideration of multiple variables:

• Solid phase selection: Compare different plate types (Maxisorp vs. biotin-coated) for optimal antigen presentation

• Antigen coating concentration: Determine optimal coating concentration through titration experiments

• Sample pre-treatment: Remove albumin and dilute serum appropriately to reduce interference

• Blocking conditions: Use protein-free blocking buffer to prevent non-specific binding

• Assay specificity controls: Include proper controls by comparing reactivity to target versus non-target proteins

• Cutoff value determination: Establish cutoff values based on receiver operating characteristic (ROC) curve analysis

• Standardization: Include reference samples in each assay to account for inter-assay variation

Research demonstrated that Maxisorp plates were superior to biotin-coated plates for detecting low concentrations of anti-EIF3A autoantibodies . The optimal coating concentration was approximately 80 ng/well, and pre-treatment of serum samples with albumin-removal resin followed by 50-fold dilution in protein-free blocking buffer improved assay performance .

How might single-cell analysis techniques enhance our understanding of EIF3E expression heterogeneity in cancer?

Single-cell analysis offers powerful approaches to explore EIF3E expression heterogeneity in cancer contexts:

• Single-cell RNA sequencing (scRNA-seq): Enables characterization of EIF3E expression patterns at transcriptional level across individual cells within tumors

• Mass cytometry (CyTOF): Allows simultaneous detection of EIF3E protein along with numerous other cancer markers at single-cell resolution

• Spatial transcriptomics: Provides information on EIF3E expression while preserving spatial context within the tumor microenvironment

• Live-cell imaging: Permits real-time monitoring of EIF3E dynamics in living cancer cells

• Multi-omics integration: Combines single-cell transcriptomics, proteomics, and epigenomics data to provide comprehensive insights

These approaches could reveal distinct cancer cell subpopulations with differential EIF3E expression patterns, potentially identifying therapy-resistant clones or cells with enhanced metastatic potential. Such insights could lead to improved cancer classification, prognostication, and treatment selection.

What are the potential applications of EIF3E/EIF3A antibodies in therapeutic development?

Beyond their diagnostic applications, EIF3E/EIF3A antibodies present several potential therapeutic avenues:

• Antibody-drug conjugates (ADCs): Utilizing anti-EIF3E antibodies to deliver cytotoxic payloads specifically to cancer cells with elevated EIF3E expression

• CAR-T cell therapy: Developing chimeric antigen receptor T cells targeting EIF3E-overexpressing cancer cells

• Functional blockade: Employing antibodies that inhibit EIF3E/EIF3A function in protein synthesis initiation

• Combination therapies: Using EIF3E/EIF3A targeting in conjunction with established cancer therapies

• Cancer stem cell targeting: Developing approaches to target EIF3E-expressing cancer stem cells that drive tumor progression

The research highlighting EIF3A as "a novel anticancer drug target" supports the therapeutic potential of targeting these translation initiation factors . The elevated expression of EIF3A in HCC and other cancers provides a rationale for exploring these therapeutic approaches, particularly for cancers with limited treatment options.

How can multi-omics approaches integrate EIF3E/EIF3A data to improve cancer diagnostics?

Multi-omics integration offers comprehensive insights by combining EIF3E/EIF3A data across biological levels:

• Integrative analysis pipeline: Develop computational frameworks that integrate genomic, transcriptomic, proteomic, and autoantibody data related to EIF3E/EIF3A

• Network biology approaches: Map EIF3E/EIF3A interactions within protein-protein interaction networks and signaling pathways

• Machine learning algorithms: Apply advanced algorithms to identify multi-omics signatures that enhance diagnostic accuracy

• Longitudinal profiling: Track changes in EIF3E/EIF3A expression and autoantibody levels over disease progression

• Population-scale analysis: Examine EIF3E/EIF3A variations across diverse patient populations to identify subgroup-specific biomarkers

Research has already demonstrated the value of combinatorial approaches, showing that simultaneous detection of anti-EIF3A autoantibody with other HCC biomarkers, including alpha-fetoprotein, improved diagnostic sensitivity from 79.4% to 85% . This supports the potential of integrated multi-marker panels for enhanced cancer diagnosis.